Edaravone Dosage

Medically reviewed by Drugs.com. Last updated on Sep 5, 2023.

Usual Adult Dose for Amyotrophic Lateral Sclerosis

Initial treatment cycle:

• Intravenous infusion: 60 mg once daily over 60 minutes for 14 days, followed by a 14-day drug-free period.
• Oral suspension: 105 mg (5 mL) once daily orally or via feeding tube in the morning after overnight fasting for 14 days, followed by a 14-day drug-free period.

Subsequent treatment cycles:

• Intravenous infusion: 60 mg once daily over 60 minutes for 10 days out of 14-day periods, followed by 14-day drug-free periods.
• Oral suspension: 105 mg (5 mL) once daily orally or via feeding tube in the morning after overnight fasting for 10 days out of 14-day periods, followed by 14-day drug-free periods.

Oral administration relative to type of food consumption:

• High-fat meal (800 -1000 calories, 50% fat): 8 hours before administration and one hour after administration.
• Low-fat meal (400-500 calories, 25% fat): 4 hours before administration and one hour after administration.
• Caloric supplement (250 calories, e.g., protein drink): 2 hours before administration and one hour after administration.

Comments:

• Administer each 60 mg dose as 2 consecutive 30 mg IV infusion bags over a total of 60 minutes (infusion rate approximately 1 mg per minute [3.33 mL per minute]).
• Discontinue infusion at first sign of hypersensitivity reaction.

Use: For the treatment of Amyotrophic lateral sclerosis (ALS)

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Precautions

CONTRAINDICATIONS: History of hypersensitivity to this drug or any of its inactive ingredients.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available.

Other Comments

Administration advice:

• IV: Do not use if the oxygen indicator turns blue or purple before opening the package. Use within 24 hours after the package is unwrapped.
• IV: Inspect visually for particulate matter and discoloration prior to administration.
• Oral: Administer on an empty stomach after an overnight fast. Food should not be consumed for 1 hour after administration, except water.
• Patients can switch from IV to oral formulation using the same dosing frequency. Follow dosing recommendations for food consumption on the oral formulation.

Storage requirements:

• IV: Store at up to 25C (77F); excursions permitted from 15 to 30C (59 to 86F). Protect from light.
• Oral: Store upright in the refrigerator between 2 to 8C (35 to 46F) and protect from light. Do not freeze.
• Oral: Patient can store upright at room temperature between 20 to 25C (68 to 77F); discard 15 days after opening and 30 days from the date of shipment if unopened.

Reconstitution/preparation techniques:

• Oral: Invert the bottle and shake vigorously for at least 30 seconds prior to opening.
• Oral: Nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tubes made of silicone, polyvinyl chloride (PVC), or polyurethane can be used. Flush the tube using a catheter-tip syringe with at least 1 ounce (30 mL) of water.
• The manufacturer's product information should be consulted for additional information.

IV compatibility:

• Do not inject other medications into the infusion bag or mix them with this drug.

Monitoring:

• Hypersensitivity/allergic reactions, anaphylaxis, asthmatic episodes (throughout treatment)

Patient advice:

• Read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
• This drug contains sodium bisulfite; notify your healthcare provider if you have sulfite sensitivity. Seek immediate care if you experience symptoms of allergic reactions.
• Females of childbearing potential should notify their healthcare provider if they are pregnant or breastfeeding.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer